Skip to main content

PERSPECTIVE article

Front. Oncol., 26 January 2023
Sec. Cancer Metabolism
This article is part of the Research Topic 365 Days of Progress In Cancer Metabolism View all 4 articles

The regulatory mechanisms of proline and hydroxyproline metabolism: Recent advances in perspective

  • Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute at Frederick (NIH), Frederick, MD, United States

For diverse human tumors, growth and metastasis are dependent on proline synthesis, but the mechanisms underlying this association are not clear. Proline incorporated into collagen is primarily synthesized from glutamine. Thus, rates of collagen synthesis are modulated by the enzymes of proline synthesis. On the other hand, the hydroxylation of collagen proline requires αKG, ascorbate and ferrous iron, substrates necessary for the epigenetic demethylation of DNA and histones. The metabolic relationship of proline and hydroxyproline degradation are initiated by distinct dehydrogenases but the respective oxidized products, P5C and OH-P5C are substrates for P5C Reductase and P5C Dehydrogenase allowing for mutual competition. This provides a model by which proline synthesis in cancer plays a role in reprogramming gene expression. The metabolism of proline and hydroxyproline are also linked to the HIF response to hypoxia. Hypoxia increased the expression of ALDH18A1, which is the limiting step in proline and collagen synthesis. Hydroxyproline increases levels of HIF-1α presumably by inhibiting its degradation. These new findings allow the suggestion that there is a regulatory axis from glutamine to proline and collagen synthesis, and the release of free hydroxyproline can feed back on the HIF pathway.

Introduction

After the initial emphasis on glucose and glutamine in cancer metabolism, interest shifted to other substrates, e.g., amino acids and lipids. The original hypothesis for the “Warburg Effect,” was to conserve carbon moieties for cell mass rather than being consumed by oxidative phosphorylation for energy (1). Similarly, the reprogramming of amino acid metabolism was thought to channel amino acids into proteinogenesis or to interconvert amino acids to safeguard the building blocks for proteins (2). A few special functions of amino acid metabolism were identified to furnish functions necessary for cellular proliferation or to mediate special metabolic pathways. These include the serine/glycine pathway for methyl transfers, glutamine to furnish amino groups for purine and pyrimidine nucleotides and branched-chain amino acids for lipogenesis (3). Especially interesting are the non-essential amino acids (NEAAs) where the biosynthetic mechanisms making them nonessential provide critical contributions to metabolism. An important metabolic system often omitted from reviews of amino acid metabolism in cancer is that for the amino acid proline (4, 5). This omission may be due to the complexities of proline metabolism, its interaction with the metabolism of hydroxyproline, and the critical function of proline in the synthesis of collagen thereby forming the infrastructure for the microenvironment. Additionally, hydroxylation of protein prolines, a metabolic reaction central to the formation of collagen, also is the mechanism responding to hypoxia (6) and also may play an essential step in metabolic epigenetics.

The features of proline synthesis and degradation were recognized since no other amino (imino) acid had a common metabolite which served as direct precursor as well as immediate degradative product (4). Due to this relationship of metabolites, a “proline cycle” was recognized. Additionally, the metabolite, pyrroline-5-carboxlate (P5C) could transfer oxidizing potential into cells to activate certain pathways, i.e., the pentose phosphate pathway (PPP) and markedly increase the formation of ribose, PRPP and nucleotides (7). The induction of proline dehydrogenase (PRODH) by P53, and the upregulation of the proline synthetic enzymes by MYC and by AKT and PI3K suggested that the proline metabolic system plays an important role in oncogenic proliferation and metabolic reprogramming (5). In clinical screening, increased PYCR1 is associated with many human cancers, (8) and knockdown of PYCR 1 in tumors transplanted into mice markedly decreased tumor growth. Additionally, the inhibition of the ALDH18A1- MYCN positive feed back loop attenuates MYCN-amplified neuroblastoma growth (9). Importantly, the availability of preformed proline does not mitigate the inability to synthesize proline suggesting either compartmentation of endogenously synthesized proline or a process channeling synthesized proline for the synthesis of collagen. This apparent routing of synthesized proline to collagen and the special metabolic role of collagen turnover has been recently reviewed (8). Furthermore, the mechanoregulatory properties of collagen and the role of Kindlin-2 and Pinch-1, two sensors of collagen stiffness caused upregulation of PYCR1 strongly suggesting that proline synthesis is linked to a functional role of collagen (10). These regulatory functions of proline metabolism and especially the relationship of collagen turnover to proline metabolism has been recently reviewed (8).

During the last 2 years, a number of new directions came from interesting findings from a number of laboratories. Although it would take a voluminous review to cover them all, I have taken the liberty of emphasizing a number of new and somewhat unexpected discoveries. These include: 1) The transitional pluripotency mediated by proline metabolism in embryonic stem cells (ESC) (11), and 2) also in cancer stemlike cells (CSC) (12); 3) The interaction between proline metabolism and hydroxyproline metabolism (13) 4) the effect of hydroxyproline with HIF-1α (13); 5) the hydroxylation of collagen and its modulation of demethylation in TET and Jmj (8); 6) In CAR-T Lymphocytes, screened by gain-of-function CRISPR screens, the discovery that PRODH2 (hydroxyproline dehydrogenase) was the only gene which significantly activated the tumorlytic effect of CAR-T cells (14). We will discuss these subjects in order and attempt to explain the mechanisms and their implications using state-of-the-art insights into proline metabolism and cancer (11).

The interaction between the metabolism of proline and hydroxyproline

An interesting finding appeared from work in hepatocellular carcinoma. The workers showed that there was markedly accelerated consumption of proline with accumulation of hydroxyproline (13). They found that hypoxia Increased the expression of ALDH18Al, which codes for pyrroline-5-carboxylate synthase and increases proline formation. Importantly, accompanying hypoxia, an increase in hydroxyproline increased the level of HIIF-1a. Since HIF-1a levels are (13) collagen, it is not surprising that there may be interaction between hydroxyproline and the hydroxylation of HIF-1α (13). It is noteworthy that several authors back in the 1980s described the phenomenon of early intracellular degradation of collagen before it is secreted to form fibrils (15). Others have shown the differential growth sensitivity to 4-cis-Hydroxy-L-proline of transformed rodent cell lines (16). One interpretation of these previous findings is the suggestion that the production of free hydroxyproline is important for cellular regulation and the only way this can occur is through hydroxylation of proline in collagen. Thus, the release of free hydroxyproline may benefit the cell with the regulatory function of hydroxyproline (Figure 1). Although the metabolism of proline in cancer has received increasing attention, the metabolism of hydroxyproline has been reviewed (17), but the metabolic interaction between these two imino acids has received little attention.

FIGURE 1
www.frontiersin.org

Figure 1 Metabolic Pathways for proline and hydroxyproline. Proline and hydroxyproline are metabolized by distinct dehydrogenases, the products are pyrroline-5-carboxylate and OH-pyrroline-5-carboxylate, respectively. Proline dehydrogenase (PRODH) and Hydroxyproline dehydrogenase (PRODH2) are distinct gene products but both are bound to mitochondrial inner membranes and donate electrons to FAD at site II. PCDH is in mitochondrial matrix and converts P5C and OH-P5C to glutamate and OH-glutamate, respectively. Both P5C and OH-P5C can be recycled to proline and hydroxyproline, respectively by generic PYCR. Since 3 isozymes of PYCR are known, preferential affinity of the isozymes for P5C and OH-P5C has not been defined. Competition between P5C and OH-P5C for PYCR1-3 and for PCDH has not been examined.

From previous work we showed that there the metabolism of hydroxyproline is distinct from and yet shares certain pathways with proline (18). Clearly the first steps in degradation of proline and hydroxyproline, respectively, are catalyzed by proline dehydrogenase (PRODH) and hydroxyproline dehydrogenase (PRODH2). Mary Efron showed no detectible difference in PRODH activity or proline metabolism in patients with hydroxyprolinemia and no deficiency of PRODH (19). In assays for both proline dehydrogenase and hydroxyproline dehydrogenase, we could find little overlap in activities, 100 fold concentrations of one did not affect the metabolism of its congener (18).

On the other hand, at the level of both P5C reductase and P5C dehydrogenase, the enzymes which convert P5C to proline and glutamate, respectively, can use OH-P5C, the product of hydroxyproline dehydrogenase as substrate to produce hydroxyproline and hydroxyglutamate, respectively (Figure 1). This property of P5C reductase was first described by Adams and Goldstone (20) with partially purified protein, and the P5C dehydrogenase was discovered in patients with Type 2 hyperprolinemia who accumulated both P5C and OH-P5C (21) and excreted both compounds in urine. With this recognition, one would expect that they may mutually inhibit each other’s activity, but this requires direct measurements using P5C and OH-P5C. Importantly, in the case of P5C reductase, one may have to revise our understanding of the 3 isozymes which may have different affinities and be inhibited differentially by OH-P5C (22). In fact, it may be that a particular isozyme may be specific for OH-P5C rather than P5C, but this would require additional studies using P5C and/or OH-P5C as substrates.

Proline metabolism mediates transitional pluripotency

During the last year, an important review was published by G. Minchiotti in Naples. She reviewed the original observation on mouse embryonic stem cells which was then extended by workers in her own laboratory (11, 23) who showed that treatment with proline preserved the pluripotent state. The mechanism underlying this effect may be due to the early primed state of pluripotency. Whether this effect is parallel to the reactivation of cancer stem-like cells has to be shown. A paper recently showed that knock down of PYCR1 and 2 effectively blocked the formation of mammospheres (12) in contradistinction to inhibitors of glutaminase which had little effect on mammosphere formation. This finding clearly defines that although glutamine serves as the main delivery source of degradation products of various amino acids and proteins, it is the synthesis of proline which is critical for forming mammospheres, an accepted criteria of renewal of cancer stem-like cells (24).

Proline metabolism and the formation of collagen

It is well-recognized that type I collagen is the most abundant protein in the human body. If hydroxyproline is considered to be posttranslationally modified, one must recognize that proline incorporated into collagen makes up about 25% of amino acids incorporated. Unexpectedly, the proline incorporated into collagen by fibroblasts and CAF’s are not from the total intracellular PRO pool, but preferentially from synthesized proline (2527). The hydroxylation of collagen proline by P4H forming hydroxyproline is the most abundant flux in the body. During the 1980s, several labs documented the early intracellular degradation of collagen before it was secreted to form fibrils (15), and the differential sensitivity to 4-cis-hydroxyproline (16) suggested that free hydroxyproline was an important regulatory metabolite which could only be formed by posttranslational modification and degradation.

Function of collagen as the major constituent of ECM and the microenvironment

Collagen is thought to play an important role between cancer cells and their microenvironment (28). For human breast cancer, ovarian and pancreatic cancers, dense collagen is thought to wall off the cancer from immune surveillance. Additionally, collagen acts as a mechanoregulator. The molecular mechanism linking ECM stiffening to proline and collagen synthesis involve Pinch-1 and Kindlin-2 (10) which translocate and activates PYCR-1. Thus, the molecular players linking mechanoregulation to the proline/collagen regulatory axis are beginning to be understood.

Collagen synthesis with hydroxylation of proline modulates activity of epigenetic dioxygenases

The putative role of collagen metabolism in influencing metabolic epigenetics has been reviewed (8, 29). Because proline biosynthesis may be rate limiting for the incorporation of proline into collagen, the rate by which hydroxylation is formed can also be influenced. Since the hydroxylation mechanism involves a dioxygenase reaction involving oxygen, alpha KG, ascorbate and ferrous iron, competition for these substrates may have metabolic consequences (Figure 2). This linkage has been suggested as the metabolic influence underlying epigenetic regulation. The coupling of proline synthesis to collagen formation and modulation of metabolic epigenetic has been reviewed (8). The concept is that the hydroxylation mechanism of collagens, its use of α-KG, ascorbate, Fe++, is similar in substrate demand as the demethylases of DNA and histones, Tet and Jmj, respectively. Thus, synthesized proline can influence the rate of collagen synthesis and provide the metabolic linkage to regulate epigenetic mechanisms.

FIGURE 2
www.frontiersin.org

Figure 2 The metabolic link between proline synthesis, collagen formation, formation of free PRO and OH-PRO and epigenetics. Collagen formation by Cancer-associated fibroblasts is linked to biosynthesized proline. The hydroxylation of procollagen, by P4-H exhausts a-KG and ascorbate which decreases demethylation by Tet and Jmj. Free hydroxyproline is formed by early intracellular collagen degradation as well as by extracellular degradation of collagen fibrils. Prolidase is necessary for the hydrolysis of imidodipeptides, i.e. proline and hydroxyproline as C-terminal dipeptides.

PRODH2 has been found on genomic screen for activation of CAR-T cells

With the objective of increasing the anti-tumor activity of CAR-T cells, workers performed a gain-of-function genomic screen using CRISPR. Surprisingly, the gene uniquely augmenting CAR-T cells was PRODH2, i.e. hydroxyproline dehydrogenase (14). Although PRODH2 is important in the degradation of collagen, there has not been any suggestion that it could play a regulatory role specifically for immune mechanisms. Whether PRODH2 is normally expressed in lymphocytes with or without immunologic stimulation remains unknown. Although PRODH and PRODH2 produce pyrroline-5-carboxylate (P5C) and hydroxy-pyrroline-5-carboxylate (OH-P5C), respectively, they are encoded by distinct genes and there is little overlap or cross-inhibition of activity. The final products of the two degradative pathways are alpha-KG for proline and glyoxylate and pyruvate for hydroxyproline.

Recent work performed on hepatocellular carcinoma has shown that proline and hydroxyproline are linked to the HIF-1α pathway (Figure 3) (13). The limiting step in proline synthesis from glutamine, ALDH18A1 is upregulated with hypoxia and importantly, synthesized proline is incorporated into collagen, hydroxylated and released as free hydroxyproline. This was found to increase HIF-1α levels to increase tumor survival. Whether this effect on HIF-1α is due to hydroxyproline or OH-P5C will require additional studies. But the mutual cross-inhibition of OH-P5C and P5C make possible the proposal of a proline-collagen-hydroxyproline axis which interacts not only with metabolic epigenetic mechanisms but also with the HIF pathway, the main response to hypoxia.

FIGURE 3
www.frontiersin.org

Figure 3 In conjunction with hypoxia, hydroxyproline increases the level of HIF-1α. Hydroxyproline augments the effects of hypoxia by increasing the levels of HIF-1α, but the site and mechanism for this effect has not been defined. It is possible that OH-PRO interacts at the HIF-1α hydroxylation step, at the recognition of hydroxylated HIF-1α by VHL or at the step of proteasomal degradation.

The relationship of glutamine and proline metabolism

The renaissance of metabolism in cancer was based on the seminal discoveries of Otto Warburg during the 1920s (1). He described the metabolic phenomenon in cancer as oxidative glycolysis. In the upsurge of metabolic oncogenesis during the 1990s, workers showed that an important reprogramming in metabolism was to spare carbons for the demands of increasing cell mass in carcinogenesis (30). Additionally, glutamine was thought to replenish the TCA cycle as well as supplying the nitrogen for nucleotide synthesis. Since the 1970s, it was recognized that glutamine was the medium of exchange for supplying carbons and nitrogen (31); excess protein was converted to glutamine in muscle and glutamine was used to supply growing tissue (intestine) as well as to function in acid-base balance (32). Little emphasis has been placed on the conversion of glutamine to proline, but convincing evidence from the relationship of proline to human cancer (33) together with the role of collagen synthesis makes it a critical agent for reprogramming. Additional work has to be done to reproduce the findings connecting proline metabolism to epigenetics through collagen synthesis and the dioxygenase mechanisms for demethylation and to the response to hypoxia through hydroxyproline turnover.

Summary

Although the regulatory functions of proline and pyrroline-5-carboxylate was first described in 1985 (4), and the phenomenological relationships of proline degradation as a reservoir of substrates in collagen and the synthetic mechanisms are related to reprogramming at the DNA and histone level (8) as well as in the response to hypoxia (13), there was no convincing evidence for the mechanisms relating proline metabolism to the survival of cancer cells. Advances during the last several years have provided suggestive evidence that these interpretations are plausible. Some of the models are speculative at present but enough evidence exists to justify their introduction and projects to provide convincing evidence. We mow propose the following: l) PYCR3 is linked to the pentose phosphate pathway for the formation of PRPP and the maintenance of ribonucleotides as well as pyridine nucleotides; 2) synthesized proline is preferentially incorporated into collagen and its hydroxylation competes for the co-substrates of the dioxygenases necessary for demethylation of DNA and histones as a molecular mechanism for reprogramming; 3) the proline/hydroxyproline pathway augments the response to hypoxia; 4) the proline synthetic pathway plays a critical role in the pluripotency of CSC; 5) although contributions to the TCA cycle is an important function of glutamine, the proline/collagen/hydroxyproline regulatory axis may be the most important regulatory function for the metabolism of glutamine.

Author contributions

The author confirms being the sole contributor of this work and has approved it for publication. Enquiries about this article can be sent to Dr. Lino Tessarollo (essarol@mail.nih.gov).

Acknowledgments

We thank the Program Director, Dr. Lino Tessarollo for supporting this work. We appreciate the fruitful discussions with Dr. David Salomon and Dr. Jonathan Keller.

Conflict of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Warburg O. On the origin of cancer cells. Science (1956) 123(3191):309–14. doi: 10.1126/science.123.3191.309

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324(5930):1029–33. doi: 10.1126/science.1160809

PubMed Abstract | CrossRef Full Text | Google Scholar

3. D'Aniello C, Cermola F, Patriarca EJ, Minchiotti G. Metabolic-epigenetic axis in pluripotent state transitions. Epigenomes (2019) 3:(3). doi: 10.3390/epigenomes3030013

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Phang JM. The regulatory functions of proline and pyrroline-5-carboxylic acid. Curr Top Cell Regul (1985) 25:91–132. doi: 10.1016/b978-0-12-152825-6.50008-4

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Phang JM. Proline metabolism in cell regulation and cancer biology: Recent advances and hypotheses. Antioxid Redox Signal (2019) 30(4):635–49. doi: 10.1089/ars.2017.7350

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 111(6):779–83. doi: 10.1172/JCI18181

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Yeh GC, Phang JM. Pyrroline-5-carboxylate stimulates the conversion of purine antimetabolites to their nucleotide forms by a redox-dependent mechanism. J Biol Chem (1983) 258(16):9774–9. doi: 10.1016/S0021-9258(17)44565-0

PubMed Abstract | CrossRef Full Text | Google Scholar

8. D'Aniello C, Patriarca EJ, Phang JM, Minchiotti G. Proline metabolism in tumor growth and metastatic progression. Front Oncol (2020) 10:776. doi: 10.3389/fonc.2020.00776

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Guo YF, Duan JJ, Wang J, Li L, Wang D, Liu XZ, et al. Inhibition of the ALDH18A1-MYCN positive feedback loop attenuates MYCN-amplified neuroblastoma growth. Sci Transl Med (2020) 12:(531). doi: 10.1126/scitranslmed.aax8694

CrossRef Full Text | Google Scholar

10. Chen K, Guo L, Wu C. How signaling pathways link extracellular mechano-environment to proline biosynthesis: A hypothesis: PINCH-1 and kindlin-2 sense mechanical signals from extracellular matrix and link them to proline biosynthesis. Bioessays (2021) 43(9):e2100116. doi: 10.1002/bies.202100116

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Minchiotti G, D'Aniello C, Fico A, De Cesare D, Patriarca EJ. Capturing transitional pluripotency through proline metabolism. Cells (2022) 11:(14). doi: 10.3390/cells11142125

CrossRef Full Text | Google Scholar

12. Greer YE, Hernandez L, Fennell EMJ, Kundu M, Voeller D, Chari R, et al. Mitochondrial matrix protease ClpP agonists inhibit cancer stem cell function in breast cancer cells by disrupting mitochondrial homeostasis. Cancer Res Commun (2022) 2(10):1144–61. doi: 10.1158/2767-9764.CRC-22-0142

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Tang L, Zeng J, Geng P, Fang C, Wang Y, Sun M, et al. Global metabolic profiling identifies a pivotal role of proline and hydroxyproline metabolism in supporting hypoxic response in hepatocellular carcinoma. Clin Cancer Res (2018) 24(2):474–85. doi: 10.1158/1078-0432.CCR-17-1707

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab (2022) 34(4):595–614 e514. doi: 10.1016/j.cmet.2022.02.009

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Baum BJ, Moss J, Breul SD, Berg RA, Crystal RG. Effect of cyclic AMP on the intracellular degradation of newly synthesized collagen. J Biol Chem (1980) 255(7):2843–7. doi: 10.1016/S0021-9258(19)85816-7

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Ciardiello F, Sanfilippo B, Yanagihara K, Kim N, Tortora G, Bassin RH, et al. Differential growth sensitivity to 4-cis-hydroxy-L-proline of transformed rodent cell lines. Cancer Res (1988) 48(9):2483–91.

PubMed Abstract | Google Scholar

17. Wu Z, Hou Y, Dai Z, Hu CA, Wu G. Metabolism, nutrition, and redox signaling of hydroxyproline. Antioxid Redox Signal (2019) 30(4):674–82. doi: 10.1089/ars.2017.7338

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Downing SJ, Phang JM, Kowaloff EM, Valle D, Smith RJ. Proline oxidase in cultured mammalian cells. J Cell Physiol (1977) 91(3):369–76. doi: 10.1002/jcp.1040910306

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Efron ML, Bixby EM, Hockaday TD, Smith LH Jr., Meshorer E. Hydroxyprolinemia. 3. the origin of free hydroxyproline in hydroxyprolinemia. collagen turnover. evidence for biosynthetic pathway in man. Biochim Biophys Acta (1968) 165(2):238–50. doi: 10.1016/0304-4165(68)90052-4

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Adams E, Goldstone A. Hydroxyproline metabolism. III. enzymatic synthesis of hydroxyproline from delta 1-pyrroline-3-hydroxy-5-carboxylate. J Biol Chem (1960) 235:3499–503. doi: 10.1016/S0021-9258(18)64497-7

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Valle D, Goodman SI, Harris SC, Phang JM. Genetic evidence for a common enzyme catalyzing the second step in the degradation of proline and hydroxyproline. J Clin Invest (1979) 64(5):1365–70. doi: 10.1172/JCI109593

PubMed Abstract | CrossRef Full Text | Google Scholar

22. De Ingeniis J, Ratnikov B, Richardson AD, Scott DA, Aza-Blanc P, De SK, et al. Functional specialization in proline biosynthesis of melanoma. PloS One (2012) 7(9):e45190. doi: 10.1371/journal.pone.0045190

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Washington JM, Rathjen J, Felquer F, Lonic A, Bettess MD, Hamra N, et al. L-proline induces differentiation of ES cells: a novel role for an amino acid in the regulation of pluripotent cells in culture. Am J Physiol Cell Physiol (2010) 298(5):C982–992. doi: 10.1152/ajpcell.00498.2009

PubMed Abstract | CrossRef Full Text | Google Scholar

24. De Francesco EM, Sotgia F, Lisanti MP. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J (2018) 475(9):1611–34. doi: 10.1042/BCJ20170164

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Karna E, Szoka L, Huynh TYL, Palka JA. Proline-dependent regulation of collagen metabolism. Cell Mol Life Sci (2020) 77(10):1911–8. doi: 10.1007/s00018-019-03363-3

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Hamanaka RB, O'Leary EM, Witt LJ, Tian Y, Gokalp GA, Meliton AY, et al. Glutamine metabolism is required for collagen protein synthesis in lung fibroblasts. Am J Respir Cell Mol Biol (2019) 61(5):597–606. doi: 10.1165/rcmb.2019-0008OC

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Kay EJ, Paterson K, Riera-Domingo C, Sumpton D, Dabritz JHM, Tardito S, et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nat Metab (2022) 4(6):693–710. doi: 10.1038/s42255-022-00582-0

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumour Biol (2014) 35(4):2871–82. doi: 10.1007/s13277-013-1511-7

PubMed Abstract | CrossRef Full Text | Google Scholar

29. D'Aniello C, Fico A, Casalino L, Guardiola O, Di Napoli G, Cermola F, et al. A novel autoregulatory loop between the Gcn2-Atf4 pathway and (L)-proline [corrected] metabolism controls stem cell identity. Cell Death Differ (2015) 22(7):1094–105. doi: 10.1038/cdd.2015.24

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Lyssiotis CA, Vander-Heiden MG, Munoz-Pinedo C, Emerling BM. Emerging concepts: linking hypoxic signaling and cancer metabolism. Cell Death Dis (2012) 3(5):e303. doi: 10.1038/cddis.2012.41

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Windmueller HG, Spaeth AE. Uptake and metabolism of plasma glutamine by the small intestine. J Biol Chem (1974) 249(16):5070–9. doi: 10.1016/S0021-9258(19)42329-6

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Taylor L, Curthoys NP. Glutamine metabolism: Role in acid-base balance*. Biochem Mol Biol Educ (2004) 32(5):291–304. doi: 10.1002/bmb.2004.494032050388

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, et al. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. Breast Cancer Res (2019) 21(1):61. doi: 10.1186/s13058-019-1141-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: shared enzymes, competition, hydroxylation, CSC, demethylation

Citation: Phang JM (2023) The regulatory mechanisms of proline and hydroxyproline metabolism: Recent advances in perspective. Front. Oncol. 12:1118675. doi: 10.3389/fonc.2022.1118675

Received: 07 December 2022; Accepted: 29 December 2022;
Published: 26 January 2023.

Edited by:

Parmanand Malvi, University of Alabama at Birmingham, United States

Reviewed by:

Mostafa A. Aboouf, University of Zurich, Switzerland

Copyright © 2023 Phang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: James M. Phang, phangj@mail.nih.gov

Deceased

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.